Home › Companies › Inovio Pharmaceuticals, Inc. › 2025-2026
Compiled from SEC Form N-PX filings and Inovio Pharmaceuticals, Inc.’s Form 8-K, filed May 20, 2026 (Item 5.07 on EDGAR). Page generated October 18, 2026.
Meeting of May 20, 2026: 11 items on Inovio Pharmaceuticals, Inc.’s Form 8-K, filed May 20, 2026: 11 without a stated outcome.
None.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Explore Inovio Pharmaceuticals, Inc. in the interactive database Compare manager voting policies
These tallies are Inovio Pharmaceuticals, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 20, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Simon X. Benito | 22,312,198 | -- | -- | 1,267,180 | 17,091,251 | 95% | Not verified | — |
| Elect Director: Roger D. Dansey, M.D. | 22,480,244 | -- | -- | 1,099,134 | 17,091,251 | 95% | Not verified | — |
| Elect Director: Ann C. Miller, M.D. | 22,544,652 | -- | -- | 1,034,726 | 17,091,251 | 96% | Not verified | — |
| Elect Director: Jacqueline E. Shea, Ph.D. | 22,560,816 | -- | -- | 1,018,562 | 17,091,251 | 96% | Not verified | — |
| Elect Director: Jay P. Shepard | 22,468,210 | -- | -- | 1,111,168 | 17,091,251 | 95% | Not verified | — |
| Elect Director: David B. Weiner, Ph.D. | 22,666,881 | -- | -- | 912,497 | 17,091,251 | 96% | Not verified | — |
| Elect Director: Wendy L. Yarno | 22,451,874 | -- | -- | 1,127,504 | 17,091,251 | 95% | Not verified | — |
| Elect Director: Lota S. Zoth | 22,455,943 | -- | -- | 1,123,435 | 17,091,251 | 95% | Not verified | — |
| 2. The ratification of the appointment by the Audit Committee of the Board of Directors of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 | 39,329,582 | 1,198,040 | 143,007 | -- | -- | 97% | Not verified | — |
| 3. The approval, on a non-binding advisory basis, of the compensation of the NEOs described in the Proxy Statement | 21,500,999 | 1,607,592 | 470,787 | -- | 17,091,251 | 93% | Not verified | — |
| 4. The approval of the amendment and restatement of the Company's Amended and Restated 2023 Omnibus Incentive Plan as described in the Proxy Statement | 21,559,350 | 1,535,940 | 484,088 | -- | 17,091,251 | 93% | Not verified | — |
This meeting is also recorded here as May 19, 2026; both records come from the same filing, so the date should be checked against it.
Source: Inovio Pharmaceuticals, Inc., Form 8-K, filed with the SEC on May 20, 2026 — read the filing on EDGAR.
Each item below shows how the 116 asset managers that disclosed a Inovio Pharmaceuticals, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 5 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
Description as filed by funds: To elect the following directors to serve for a term ending upon the 2027 Annual Meeting of Stockholders and until their successors are elected and qualified: Ann C. Miller, M.D.
Inovio Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Ann C. Miller, M.D.”): 22,544,652 for, 1,034,726 withheld, per its Form 8-K filed May 20, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 96% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 11 asset managers below reported 9,861,694 for, 359 withheld, 896 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 9,073,636 | 0 | 0 | 0 | For |
| Vanguard | 720,573 | 0 | 896 | 0 | For |
| BlackRock | 36,836 | 0 | 0 | 0 | For |
| Goldman Sachs | 10,931 | 0 | 0 | 0 | For |
| Equitable | 7,827 | 0 | 0 | 0 | For |
| Victory Capital | 7,821 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 1,600 | 0 | 0 | 0 | For |
| John Hancock | 1,257 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 1,008 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 0 | 0 | 0 | 359 | Withhold |
| Guggenheim | 205 | 0 | 0 | 0 | For |
Combines 5 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
Description as filed by funds: To elect the following directors to serve for a term ending upon the 2027 Annual Meeting of Stockholders and until their successors are elected and qualified: David B. Weiner, Ph.D.
Inovio Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: David B. Weiner, Ph.D.”): 22,666,881 for, 912,497 withheld, per its Form 8-K filed May 20, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 96% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 11 asset managers below reported 9,861,694 for, 359 withheld, 896 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 9,073,636 | 0 | 0 | 0 | For |
| Vanguard | 720,573 | 0 | 896 | 0 | For |
| BlackRock | 36,836 | 0 | 0 | 0 | For |
| Goldman Sachs | 10,931 | 0 | 0 | 0 | For |
| Equitable | 7,827 | 0 | 0 | 0 | For |
| Victory Capital | 7,821 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 1,600 | 0 | 0 | 0 | For |
| John Hancock | 1,257 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 1,008 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 0 | 0 | 0 | 359 | Withhold |
| Guggenheim | 205 | 0 | 0 | 0 | For |
Combines 6 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
Description as filed by funds: To elect the following directors to serve for a term ending upon the 2027 Annual Meeting of Stockholders and until their successors are elected and qualified: Jacqueline E. Shea, Ph.D.
Inovio Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Jacqueline E. Shea, Ph.D.”): 22,560,816 for, 1,018,562 withheld, per its Form 8-K filed May 20, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 96% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 11 asset managers below reported 9,861,694 for, 359 withheld, 896 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 9,073,636 | 0 | 0 | 0 | For |
| Vanguard | 720,573 | 0 | 896 | 0 | For |
| BlackRock | 36,836 | 0 | 0 | 0 | For |
| Goldman Sachs | 10,931 | 0 | 0 | 0 | For |
| Equitable | 7,827 | 0 | 0 | 0 | For |
| Victory Capital | 7,821 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 1,600 | 0 | 0 | 0 | For |
| John Hancock | 1,257 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 1,008 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 0 | 0 | 0 | 359 | Withhold |
| Guggenheim | 205 | 0 | 0 | 0 | For |
Combines 5 wordings of this item as funds reported it.
95% Majority: yes · of votes cast
Description as filed by funds: To elect the following directors to serve for a term ending upon the 2027 Annual Meeting of Stockholders and until their successors are elected and qualified: Jay P. Shepard
Inovio Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Jay P. Shepard”): 22,468,210 for, 1,111,168 withheld, per its Form 8-K filed May 20, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 95% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 11 asset managers below reported 9,861,694 for, 359 withheld, 896 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 9,073,636 | 0 | 0 | 0 | For |
| Vanguard | 720,573 | 0 | 896 | 0 | For |
| BlackRock | 36,836 | 0 | 0 | 0 | For |
| Goldman Sachs | 10,931 | 0 | 0 | 0 | For |
| Equitable | 7,827 | 0 | 0 | 0 | For |
| Victory Capital | 7,821 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 1,600 | 0 | 0 | 0 | For |
| John Hancock | 1,257 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 1,008 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 0 | 0 | 0 | 359 | Withhold |
| Guggenheim | 205 | 0 | 0 | 0 | For |
Combines 5 wordings of this item as funds reported it.
95% Majority: yes · of votes cast
Description as filed by funds: To elect the following directors to serve for a term ending upon the 2027 Annual Meeting of Stockholders and until their successors are elected and qualified: Lota S. Zoth
Inovio Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Lota S. Zoth”): 22,455,943 for, 1,123,435 withheld, per its Form 8-K filed May 20, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 95% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 11 asset managers below reported 9,861,694 for, 359 withheld, 896 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 9,073,636 | 0 | 0 | 0 | For |
| Vanguard | 720,573 | 0 | 896 | 0 | For |
| BlackRock | 36,836 | 0 | 0 | 0 | For |
| Goldman Sachs | 10,931 | 0 | 0 | 0 | For |
| Equitable | 7,827 | 0 | 0 | 0 | For |
| Victory Capital | 7,821 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 1,600 | 0 | 0 | 0 | For |
| John Hancock | 1,257 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 1,008 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 0 | 0 | 0 | 359 | Withhold |
| Guggenheim | 205 | 0 | 0 | 0 | For |
Combines 5 wordings of this item as funds reported it.
95% Majority: yes · of votes cast
Description as filed by funds: To elect the following directors to serve for a term ending upon the 2027 Annual Meeting of Stockholders and until their successors are elected and qualified: Roger D. Dansey, M.D.
Inovio Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Roger D. Dansey, M.D.”): 22,480,244 for, 1,099,134 withheld, per its Form 8-K filed May 20, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 95% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 11 asset managers below reported 9,861,694 for, 359 withheld, 896 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 9,073,636 | 0 | 0 | 0 | For |
| Vanguard | 720,573 | 0 | 896 | 0 | For |
| BlackRock | 36,836 | 0 | 0 | 0 | For |
| Goldman Sachs | 10,931 | 0 | 0 | 0 | For |
| Equitable | 7,827 | 0 | 0 | 0 | For |
| Victory Capital | 7,821 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 1,600 | 0 | 0 | 0 | For |
| John Hancock | 1,257 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 1,008 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 0 | 0 | 0 | 359 | Withhold |
| Guggenheim | 205 | 0 | 0 | 0 | For |
Combines 5 wordings of this item as funds reported it.
95% Majority: yes · of votes cast
Description as filed by funds: To elect the following directors to serve for a term ending upon the 2027 Annual Meeting of Stockholders and until their successors are elected and qualified: Simon X. Benito
Inovio Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Simon X. Benito”): 22,312,198 for, 1,267,180 withheld, per its Form 8-K filed May 20, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 95% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 11 asset managers below reported 9,861,694 for, 359 withheld, 896 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 9,073,636 | 0 | 0 | 0 | For |
| Vanguard | 720,573 | 0 | 896 | 0 | For |
| BlackRock | 36,836 | 0 | 0 | 0 | For |
| Goldman Sachs | 10,931 | 0 | 0 | 0 | For |
| Equitable | 7,827 | 0 | 0 | 0 | For |
| Victory Capital | 7,821 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 1,600 | 0 | 0 | 0 | For |
| John Hancock | 1,257 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 1,008 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 0 | 0 | 0 | 359 | Withhold |
| Guggenheim | 205 | 0 | 0 | 0 | For |
Combines 5 wordings of this item as funds reported it.
95% Majority: yes · of votes cast
Description as filed by funds: To elect the following directors to serve for a term ending upon the 2027 Annual Meeting of Stockholders and until their successors are elected and qualified: Wendy L. Yarno
Inovio Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Wendy L. Yarno”): 22,451,874 for, 1,127,504 withheld, per its Form 8-K filed May 20, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 95% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 11 asset managers below reported 9,861,694 for, 359 withheld, 896 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 9,073,636 | 0 | 0 | 0 | For |
| Vanguard | 720,573 | 0 | 896 | 0 | For |
| BlackRock | 36,836 | 0 | 0 | 0 | For |
| Goldman Sachs | 10,931 | 0 | 0 | 0 | For |
| Equitable | 7,827 | 0 | 0 | 0 | For |
| Victory Capital | 7,821 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 1,600 | 0 | 0 | 0 | For |
| John Hancock | 1,257 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 1,008 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 0 | 0 | 0 | 359 | Withhold |
| Guggenheim | 205 | 0 | 0 | 0 | For |
Combines 2 wordings of this item as funds reported it.
93% Majority: yes · of votes cast
Description as filed by funds: TO APPROVE AN AMENDMENT AND RESTATEMENT OF OUR AMENDED AND RESTATED 2023 OMNIBUS INCENTIVE PLAN.
Inovio Pharmaceuticals, Inc.’s own tally for this item (“4. The approval of the amendment and restatement of the Company's Amended and Restated 2023 Omnibus Incentive Plan as described in the Proxy Statement”): 21,559,350 for, 1,535,940 against, per its Form 8-K filed May 20, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 93% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 12 asset managers below reported 9,901,532 for, 1,255 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 9,073,636 | 0 | 0 | 0 | For |
| Vanguard | 720,573 | 896 | 0 | 0 | For |
| Eversept Partners, LP | 39,838 | 0 | 0 | 0 | For |
| BlackRock | 36,836 | 0 | 0 | 0 | For |
| Goldman Sachs | 10,931 | 0 | 0 | 0 | For |
| Equitable | 7,827 | 0 | 0 | 0 | For |
| Victory Capital | 7,821 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 1,600 | 0 | 0 | 0 | For |
| John Hancock | 1,257 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 1,008 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 0 | 359 | 0 | 0 | Against |
| Guggenheim | 205 | 0 | 0 | 0 | For |
Combines 3 wordings of this item as funds reported it.
93% Majority: yes · of votes cast
Description as filed by funds: To approve, on a non-binding advisory basis, the resolution regarding compensation of our named executive officers described in the accompanying proxy statement.
Inovio Pharmaceuticals, Inc.’s own tally for this item (“3. The approval, on a non-binding advisory basis, of the compensation of the NEOs described in the Proxy Statement”): 21,500,999 for, 1,607,592 against, per its Form 8-K filed May 20, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 93% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 9,073,636 | 0 | 0 | 0 | For |
| Vanguard | 721,468 | 1 | 0 | 0 | For |
| BlackRock | 36,836 | 0 | 0 | 0 | For |
| Goldman Sachs | 10,931 | 0 | 0 | 0 | For |
| Equitable | 7,827 | 0 | 0 | 0 | For |
| Victory Capital | 7,821 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 1,600 | 0 | 0 | 0 | For |
| John Hancock | 1,257 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 1,008 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 359 | 0 | 0 | 0 | For |
| Guggenheim | 205 | 0 | 0 | 0 | For |
| FORUM FUNDS | 2 | 0 | 0 | 0 | For |
Fund voting reports, all 12 managers: 9,862,950 for, 1 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 8,563,280 | 0 | 0 | 0 | For |
| Janus Henderson | 5,896,322 | 0 | 0 | 0 | For |
| Boxer Capital Management, LLC | 2,120,122 | 0 | 0 | 0 | For |
| DE Shaw | 1,304,683 | 0 | 0 | 0 | For |
| ADAR1 Capital Management, LLC | 1,286,407 | 0 | 0 | 0 | For |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 804,958 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 668,904 | 0 | 0 | 0 | For |
| Two Sigma | 167,556 | 0 | 0 | 0 | For |
| BlackRock | 104,894 | 0 | 0 | 0 | For |
| Northern Trust | 98,341 | 0 | 0 | 0 | For |
| Vanguard | 80,859 | 0 | 0 | 0 | For |
| GMT CAPITAL CORP | 69,311 | 0 | 0 | 0 | For |
| MARSHALL WACE, LLP | 60,294 | 0 | 0 | 0 | For |
| State Street | 50,310 | 0 | 0 | 0 | For |
| CIBC Private Wealth Group LLC | 50,000 | 0 | 0 | 0 | For |
| Green Alpha Advisors, LLC | 0 | 47,404 | 0 | 0 | Against |
| GeoWealth Management, LLC | 37,147 | 0 | 0 | 0 | For |
| Goldman Sachs | 17,903 | 0 | 0 | 0 | For |
| STEPHENS INC /AR/ | 15,500 | 0 | 0 | 0 | For |
| Renaissance | 13,368 | 0 | 0 | 0 | For |
| 683 Capital Management, LLC | 13,305 | 0 | 0 | 0 | For |
| HighTower Advisors, LLC | 11,116 | 0 | 0 | 0 | For |
| PNC BANK, NATIONAL ASSOCIATION | 8,958 | 0 | 0 | 0 | For |
| Victory Capital | 7,821 | 0 | 0 | 0 | For |
| STIFEL NICOLAUS & CO INC \MO\ | 6,306 | 0 | 0 | 0 | For |
Institutional-manager reports, all 108 managers: 21,488,420 for, 54,477 against, 98 not voted. Showing the 25 largest; see all in the interactive database.
97% Majority: yes · of votes cast
Description as filed by funds: TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2026.
Inovio Pharmaceuticals, Inc.’s own tally for this item (“2. The ratification of the appointment by the Audit Committee of the Board of Directors of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026”): 39,329,582 for, 1,198,040 against, per its Form 8-K filed May 20, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 11 asset managers below reported 9,862,173 for, 776 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 9,073,636 | 0 | 0 | 0 | For |
| Vanguard | 721,052 | 417 | 0 | 0 | For |
| BlackRock | 36,836 | 0 | 0 | 0 | For |
| Goldman Sachs | 10,931 | 0 | 0 | 0 | For |
| Equitable | 7,827 | 0 | 0 | 0 | For |
| Victory Capital | 7,821 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 1,600 | 0 | 0 | 0 | For |
| John Hancock | 1,257 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 1,008 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 0 | 359 | 0 | 0 | Against |
| Guggenheim | 205 | 0 | 0 | 0 | For |
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 82,273,237 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Fidelity | 11.03% |
| 2 | Vanguard | 0.88% |
| 3 | BlackRock | 0.04% |
| 4 | Goldman Sachs | 0.01% |
| 5 | Equitable | <0.01% |
| 6 | Victory Capital | <0.01% |
| 7 | BRIDGEWAY FUNDS INC | <0.01% |
| 8 | John Hancock | <0.01% |
| 9 | Blackstone Alternative Investment Funds | <0.01% |
| 10 | Advisors' Inner Circle Fund III | <0.01% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Fidelity | 10.41% |
| 2 | Janus Henderson | 7.17% |
| 3 | Boxer Capital Management, LLC | 2.58% |
| 4 | DE Shaw | 1.59% |
| 5 | ADAR1 Capital Management, LLC | 1.56% |
| 6 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 0.98% |
| 7 | GEODE CAPITAL MANAGEMENT, LLC | 0.81% |
| 8 | Two Sigma | 0.20% |
| 9 | BlackRock | 0.13% |
| 10 | Northern Trust | 0.12% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| RA Capital Management, L.P. | 12.96% | 13G |
| FMR (Fidelity) | 11.35% | 13F |
| HIGHBRIDGE CAPITAL MANAGEMENT LLC | 7.52% | 13G |
| Vanguard Capital Management | 5.06% | 13G |
| Alyeska Investment Group, L.P. | 4.86% | 13G |
| Vanguard Group | 4.03% | 13F |
| D.E. Shaw | 2.69% | 13F |
| Millennium Management | 1.71% | 13F |
| BlackRock | 0.80% | 13F |
| Renaissance Technologies | 0.78% | 13F |
Percentages above are of 82,273,237 shares outstanding, as reported by Inovio Pharmaceuticals, Inc. on its Form 10-Q dated May 12, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Inovio Pharmaceuticals, Inc.’s 10-Q dated May 12, 2026. This page is a static snapshot rebuilt weekly on October 18, 2026; a live search always shows the current data.
At Inovio Pharmaceuticals, Inc.'s shareholder meeting held May 20, 2026, in the 2025-2026 proxy season, 116 asset managers reported how they voted on 11 ballot items in their SEC Form N-PX filings, covering 398 separate fund positions. On the most widely held item on that ballot — To approve, on a non-binding advisory basis, the resolution regarding compensation of our named… — FOR was 93% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Inovio Pharmaceuticals, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 20, 2026.
Inovio Pharmaceuticals, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).
Download data (CSV): ballot items · votes by manager · column guide.